Premium
Peptide Receptor Radionuclide Treatment and (131)I‐MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas
Author(s) -
Nastos Konstantinos,
Cheung Vincent T.F.,
Toumpanakis Christos,
Navalkissoor Shaunak,
Quigley AnneMarie,
Caplin Martyn,
Khoo Bernard
Publication year - 2017
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.24553
Subject(s) - radionuclide therapy , medicine , progression free survival , paraganglioma , nuclear medicine , chemotherapy , oncology , surgery
BACKGROUND AND OBJECTIVES Radionuclide therapy has been used to treat patients with progressive/metastatic paragangliomas (PGLs) and phaeochromocytomas (PCCs). The aim of the present study is to retrospectively compare the therapeutic outcomes of these modalities in patients with progressive/metastatic PCCs and PGLs. METHODS Patients with progressive/metastatic PGLs and PCCs that were subjected to radionuclide treatment in our department were retrieved from our department's database for the period 1998‐2013. Overall survival (OS), progression free survival (PFS), event free survival (EFS), and response to treatment were calculated. Treatment toxicity was documented. RESULTS Twenty‐two patients with progressive/metastatic PGLs or PCCs were treated with either (131)I‐MIBG, (90)Y‐DOTATATE or (177)Lu‐DOTATATE. A total of 30 treatments were administered (16 treatments with (131)I‐MIBG, 2 with (177)Lu‐DOTATATE, and 12 with (90)Y‐DOTATATE. Patients treated with PRRT had increased PFS and response to treatment compared to (131)I‐MIBG treated patients ( P < 0.05). However, difference in OS was non significant ( P = 0.09). There was no difference in major toxicities between groups. When comparing only patients with PGLs, OS, PFS, EFS, and response to treatment were significantly higher in the PRRT treatment group. CONCLUSION PRRT treatment offers increased OS, PFS, EFS, and response to treatment compared to (131)I‐MIBG therapy in patients with progressive/malignant PGLs.